TREATMENT OF OVARIAN CANCER WITH SB75, A LHRH ANTAGONIST

说明：（申请人的摘要）激素已被证明影响 上皮性卵巢癌的生长特点，但其 作用机制尚不清楚。 特别地，低亲和力和高亲和力 LHRH受体已在卵巢肿瘤细胞上得到证实。 此外，LHRH 激动剂已成功用于卵巢癌的II期临床研究， carcinoma. 本项目将研究的抗肿瘤活性， 西曲瑞克，第一个适合临床使用的LHRH拮抗剂。 一项II期 西曲瑞克的研究将在晚期复发性 卵巢癌 本研究包括药理学研究 不同剂量水平的西曲瑞克，以确定内分泌抑制 这种药物在这些卵巢切除患者中的作用。 为了 了解一些卵巢癌的激素依赖性，我们将 评价激素和生长因子受体对 用西曲瑞克处理的卵巢肿瘤细胞的膜。 实验室结果 将获得的结果与临床反应进行比较。 最终目标是 预测哪种肿瘤对这种LHRH拮抗剂敏感， 适用于临床使用的相关预后因素。

DESCRIPTION: (Applicant's Abstract) Hormones have been shown to influence the growth characteristics of epithelial ovarian carcinoma, but their mechanism of action is still unclear. In particular, low and high affinity LHRH receptors have been demonstrated on ovarian tumor cells. Also, LHRH agonists have been used successfully in phase II clinical studies of ovarian carcinoma. This project will investigate the antitumor activity of Cetrorelix, the first LHRH antagonist suitable for clinical use. A phase II study of Cetrorelix will be performed on patients with advanced recurrent ovarian cancer. Included in this study is a pharmacological investigation of different dose levels of Cetrorelix to determine the endocrine inhibitory effect of this drug in these ovariectomized patients. In order to understand the hormonal dependency of some ovarian carcinomas, we will evaluate the modulation of hormone and growth factor receptors on the membrane of ovarian tumor cells treated with Cetrorelix. Laboratory results obtained will be compared to clinical responses. The ultimate goal is to predict which tumor is sensitive to this LHRH antagonist by identifying relevant prognostic factors applicable to clinical use.